$AKESO (09926.HK)$The stock price opened sharply higher today. As of press release, it rose 35.63% to HK$43.4, with a turnover of HK$1,644 billion.

According to the news, Kang Fang Biotech announced that the registered phase III clinical trial AK112-303 (Harmoni-2), the world's first self-developed novel bispecific antibody drug, compared Pabolibu monotherapy with first-line treatment of PD-L1 expression positive (PD-L1TPS≥ 1%) with locally advanced or metastatic non-small cell lung cancer (NSCLC), AK112-303 (Harmoni-2), a pre-set mid-term analysis conducted by the Independent Data Monitoring Committee (IDMC) showed that survival (PFS) with no progress was achieved Main research endpoints .

Patients in the Evosi group, including those with low PD-L1 expression (TPS1— 49%), high PD-L1 expression (TPS ≥ 50%), and other high-risk patients, all had significant clinical benefits. The test results showed that in the intended treatment group (ITT), the evosil group significantly prolonged PFS compared to the pabolizil group, and the risk ratio (HR) was significantly better than expected. The overall safety of the Evosi group is good, and there are no new safety signals.

edit/new